Overview Financials News + Filings Key Docs Ownership Insiders
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 03/06/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 03/03/2023 |
SC 13D/A
| Sofinnova Capital IX reports a 0% stake in CinCor Pharma, Inc. |
| 03/01/2023 |
SC 13D/A
| Sofinnova Venture Partners X, L.P. reports a 0% stake in CinCor Pharma, Inc. |
| 02/28/2023 |
SC 13D/A
| 5AM Ventures VI, L.P. reports a 0% stake in CinCor Pharma, Inc. |
| 02/28/2023 |
4
| 5AM Partners VI, LLC (10% Owner) has filed a Form 4 on CinCor Pharma, Inc. |
| 02/28/2023 |
SC 13D/A
| GENERAL ATLANTIC, L.P. reports a 0% stake in CinCor Pharma, Inc. |
| 02/27/2023 |
4
| HEALY JAMES (10% Owner) has filed a Form 4 on CinCor Pharma, Inc. |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 0.0 | 3.9 |
| Revenue growth | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 5.1 |
| Gross profit | 0.0 | 0.0 | -1.2 |
| Gross margin | | | -30.8% |
| Selling, general and administrative | 42.5 | 21.1 | |
| General and administrative | | | 1.2 |
| EBIT | -34.6 | -19.9 | 5.1 |
| EBIT margin | | | 130.8% |
| Pre-tax income | -50.4 | -22.3 | 5.0 |
| Income taxes | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% |
| Net income | -50.4 | -22.3 | 5.0 |
| Net margin | | | 128.2% |
| |
| Diluted EPS | ($32.52) | ($17.84) | $4.03 |
| Shares outstanding (diluted) | 1.5 | 1.3 | 1.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|